Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: James Perry who wrote (314)	4/8/1998 9:48:00 AM
From: Renee	Respond to of 1025

The following is posted from the article ECL Detection for Development of Immunoassays and DNA Probe Assays for Clinical Diagnostics which appeared in Clinical Chemistry, vol. 37, No. 9,1991. Some of the advantages of this technique include the following: 1. The method involves no radioisotopes, eliminating disposal and lifetime problems inherent in radioimmunoassays.(in other words no radioactive materials used) 2. ECL provides for extremely sensitive label detection at subpicomolar concentrations, as well as an extremely wide dynamic range of greater than six orders of magnitude. 3. The metal-ligand labels are extremely stable, having shelf lives of longer than one year at room temperature. Labeled proteins are similarly stable if stored at 2-5 Celsius. 4. The label is extremely versatile: it can be chemically activated with several different reactive groups to provide for easy labeling of haptens, antibodies, and nucleic acids as well as other molecules. 5. Because of the label's low molecular mass and its hydrophilicity, immunoglobulins can readily be labeled with > 20 label molecules per antibody without affecting antibody solubility or immunoreactivity. Similarly, the label does not affect the specificity or hybridization of DNA probes. 6. Assay development is accelerated by the simplicity and versatility of the technique. Both immunoassay and DNA probe assay detection use common instrumentation and very similar assay formats. The technique is easily adaptable to the measurement of both large and small analytes with both high sensitivity and wide dynamic range. Assays can be formatted as either seperation or nonseperation. 7. The detection is rapid, requiring only a few seconds for quantification. 8. Finally, the instrumentation required is not complicated, and there are no unique constraints on the disposable portions of the assay; these properties allow the rapid development of automated instruments for both the clinical immunoassay and DNA probe assay markets. I post this to reiterate the superiority of the ECL process. With the stock having risen from 13 to 45 in 3 months some people may consider taking their profits now. Undoubtedly some momentum players are in the stock and if they leave their will be some short term volatility. Just remember if they are negotiating a buyout of the Roche license at a range of say 500-800 million that represents 30-47 dollars cash per share for this piece of their business. Also consider if management is willing to sell the license they must consider the remaining portion to be more valuable. Montgomery values the POC application at $40. I personally won't consider selling until $70-80 if then.